Do you want to read an article? Please log in or register.
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
Genitourinary Cancer
Related content
Genitourinary Cancer
Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program
Clin Genitourin Cancer.
Papazoglou D, Wannesson L, Berthold D, Cathomas R, Gillessen S, Rothermundt C, Hasler L, Winterhalder R, Barth A, Mingrone W, Nussbaum CU, von Rohr L, von Burg P, Schmid M, Richner J, Baumann S Kühne R, Stenner F, Rothschild SI
doi: 10.1016/j.clgc.2016.06.011.
Genitourinary Cancer
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
N Engl J Med.
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M, PROSPER Investigators.
doi: 10.1056/NEJMoa2003892.
Genitourinary Cancer
Prostate Cancer Highlights from ASCO GU 2021: Cutting-Edge Results
healthbook TIMES Oncology Hematology
Alexander Meisel
doi: DOI: 10.36000/hbT.OH.2021.08.041
Gastrointestinal CancerGenitourinary Cancer
Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial
Cancer.
Loriot Y, Fizazi K, de Bono JS, Forer D, Hirmand M, Scher HI
doi: 10.1002/cncr.30336.
Genitourinary Cancer
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
N Engl J Med.
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung, Krivoshik A, Sternberg CN
doi: 10.1056/NEJMoa1800536.
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
Genitourinary Cancer
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial
Eur Urol.
Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, Parli T, Rosbrook B, van Os S, Beer TM
doi: 10.1016/j.eururo.2020.04.061.
COMMENTED
Genitourinary Cancer
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol.
Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, Bossi A, den Eertwegh AJMV, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Danielli R, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, McHenry MB, Chen A, Logothetis C, CA184-043, Investigators
doi: 10.1016/j.eururo.2020.07.032.
COMMENTED
Genitourinary Cancer
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
N Engl J Med.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR, ARAMIS Investigators.
doi: 10.1056/NEJMoa2001342.